Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Christopher Cannon MD

Christopher P. Cannon MD

Education Director, Cardiovascular Innovation, Cardiovascular Division, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School; Remote faculty, Clinician-Scientist, CPC Clinical Research Institute, Boston, Massachusetts

Dr. Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital. He serves as Education Director in the Cardiovascular Innovation group and has recently joined the remote faculty as a Clinician Scientist at the CPC Clinical Research Institute. Previously, he worked for 25 years as an investigator in the TIMI Study Group, then for 9 years the Harvard Clinical Research Institute/Baim Institute.

He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.

Dr. Cannon has published over 1000 original articles, reviews, or book chapters in the field of acute coronary syndromes and prevention and has authored or edited 20 books. He has received numerous awards, including leadership awards from the American College of Cardiology, American Heart Association and National Lipid Association.

He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI and VERTIS CV trials.    He is currently working on clinical trials, registries, and quality improvement projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention.  In his role at Cardiovascular Innovation, he is helping implement quality improvement programs using telemedicine for lipids, hypertension, and diabetes, and at CPC Clinical Research he helps lead pragmatic clinical trials.


Dr. Cannon reports in calendar years 2021 to 2023:

  • Research Grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Daiichi Sankyo, Merck, Novo Nordisk, Pfizer
  • Consulting fees from Amryt/Chiesi, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Biogen, BI, BMS, CSL Behring, Eli Lilly, Janssen, Lexicon, Merck, Milestone, Pfizer, Rhoshan, Sanofi

Dr. Cannon serves on Data and Safety Monitoring Boards for the Applied Therapeutics, Areteia and Novo Nordisk.